04/01/2012 Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

12/01/2011 Pharmacokinetics and Safety of Single and Multiple Doses of ACHN-490 Injection Administered Intravenously in Healthy Subjects

Robert T. Cass, Carter D. Brooks, Nancy A. Havrilla, Kenneth J. Tack, Marie T. Borin, Don Young and Jon B. Bruss
Antimicrob. Agents Chemother. December 2011 vol. 55 no. 12 5874-5880
Access this publication at sciencedirect.com [purchase or paid subscription required]

10/24/2011 In Vitro Activity of ACHN-490 Tested Against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2011: CANWARD Surveillance Study
IDSA 2011, poster # 597

10/01/2011 Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals

09/21/2011 In Vivo Activity of Plazomicin (previously ACHN-490) Against Causative Agents of Nosocomial Pneumonia in a Murine Neutropenic Lung Model

N Reyes, JV McKinnell, RD Matias, LA Feeney, RT Cass, and RT Cirz
Achaogen Inc.
ICAAC 2011, poster # A2-045c

09/21/2011 Activity of Plazomicin (previously ACHN-490) Against Gram-Positive and Gram-Negative Bacteria in the Presence of Pulmonary Surfactant

LA Feeney, R Matias, G Miller, J Bruss, E Armstrong
Achaogen Inc.
ICAAC 2011, poster # C1-611

09/21/2011 In Vitro Activity of ACHN-490 Against Recent Respiratory Tract Pathogens

05/11/2011 Activity of ACHN-490 against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli and Enterobacter spp. from Athens, Greece

I. Galani, M. Souli, G. Daikos, Z. Chrysouli, G. Poulakou, M. Psichogiou, T. Panayea, A. Argyropoulou , I. Stefanou, G. Plakias, H. Giamarellou, G. Petrikkos
4th Dept Internal Medicine, Athens Medical School, Attikon University General Hospital
ECCMID 2011, poster # P1147

05/11/2011 ACHN-490 as a potential addition to the antimicrobial armamentarium in ICUs with high levels of resistant organisms

05/01/2011 Activity of ACHN-490 Tested Alone and in Combination with Other Agents against Pseudomonas aeruginosa

Pankuch GA, Lin G, Kubo A, Armstrong ES, Appelbaum PC, Kosowska-Shick K.
Antimicrobial Agents and Chemotherapy, May 2011,p. 2463-2465, Vol. 55, No. 5
Access this publication at aac.asm.org

01/31/2011 In vivo efficacy of the next-generation aminoglycoside ACHN-490 in murine infection models

12/03/2010 Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City

11/14/2010 Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates

10/10/2010 Efficacy of ACHN-490 in a Murine Urinary Tract Infection Model with Escherichia coli

10/10/2010 Activity and Efficacy of ACHN-490, a Broad-Spectrum Next-Generation Aminoglycoside, Against Yersinia pestis and Francisella tularensis

10/10/2010 Population Pharmacokinetics of ACHN-490 Injection in Healthy Subjects

10/01/2010 Combating evolution with intelligent design: the neoglycoside ACHN-490
Eliana S Armstrong and George H Miller
Current Opinion in Microbiology, Volume 13, Issue 5, October 2010, Pages 565-573
Access this publication at ScienceDirect.com

09/16/2010 Pharmacokinetics (PK) and Safety of ACHN-490 Injection Administered Intravenously for Five Days in Healthy Human Subjects

09/16/2010 Activity of ACHN-490 Against Isolates of Methicillin-resistant Staphylococcus aureus (MRSA) from Patients in U.S. Hospitals

09/16/2010 Activity of ACHN-490 ± Cefepime, Doripenem, Imipenem or Piperacillin/tazobactam against 25 P. aeruginosa by Synergy Time-Kill

09/16/2010 Activity of ACHN-490, a Neoglycoside, against E. coli (EC) and K. pneumoniae (KP) Isolates from New York City (NYC)

08/30/2010 Synthesis and Spectrum of the Neoglycoside ACHN-490
Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE.
Antimicrob. Agents Chemother. doi:10.1128/AAC.00572-10
Access this publication at aac.asm.org

08/05/2010 ACHN-490 Overview: Web Conference

Hosted in August 2010 by J. Kevin Judice, CEO & CSO
 - Listen to a recording of the web conference (use password: 90215265, pop-up windows must be enabled in your browser)
 - Download a PDF of the presentation

07/31/2010 Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City

Landman D, Babu E, Shah N, Kelly P, Bäcker M, Bratu S, Quale J.
J Antimicrob Chemother. 2010 Jul 31.
Access this publication at jac.oxfordjournals.org

07/30/2010 New aminoglycoside antibiotics
Paola Dozzo & Heinz E Moser
Expert Opin. Ther. Patents (2010) 20(10)
Access this publication at informahealthcare.com

02/09/2010 Antistaphylococcal Activity of ACHN-490 Tested Alone and in Combination with Other Agents by Time-Kill Assay
Gengrong Lin, Lois M. Ednie, and Peter C. Appelbaum
Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.01350-09
Access this publication at aac.asm.org

10/01/2009 ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae Isolates
Andrea Endimiani, Kristine M. Hujer, Andrea M. Hujer, Eliana S. Armstrong, Yuvraj Choudhary, James B. Aggen, and Robert A. Bonomo
Antimicrobial Agents and Chemotherapy, October 2009, p. 4504-4507, Vol. 53, No. 10
Access this publication at aac.asm.org

09/13/2009 Activity of the Neoglycoside ACHN-490 Against a Contemporary Collection of Clinical Isolates Including Antimicrobial-Resistant Strains
RN Jones, ES Armstrong, JB Aggen, DJ Biedenbach, GH Miller
JMI Laboratories, Achaogen Inc.
ICAAC 2009, poster # F1-846a

09/13/2009 Pharmacokinetics of the Novel Neoglycoside ACHN-490 in Mouse, Rat, and Dog
Robert T. Cass, Jenny V. McKinnell, Bo Xie, Dane E. Karr, Donald E. Schmidt Jr.
Achaogen, Inc.
ICAAC 2009, poster # F1-846

09/13/2009 In Vivo Efficacy of the Neoglycoside ACHN-490 Against Enterobacteriaceae and MRSA
Noe Reyes, James B. Aggen, Corwin F. Kostrub
Achaogen, Inc.
ICAAC 2009, poster # F1-845

09/13/2009 Activity of ACHN-490 in Combination with Daptomycin, Ceftobiprole, or Linezolid Against 25 methicillin-resistant Staphylococcus aureus by Synergy Time-kill
Gengrong Lin, Lois M. Ednie, Peter C. Appelbaum
Department of Pathology, Hershey Medical Center
ICAAC 2009, poster # F1-844

09/13/2009 Activity of ACHN-490 Against Complicated Urinary Tract Infection (cUTI) Pathogens From the United States (USA) and Europe (EU)
DJ Biedenbach, RN Jones, ES Armstrong, JB Aggen, GH Miller
JMI Laboratories, Achaogen Inc.
ICAAC 2009, poster # F1-843

09/13/2009 Activity of ACHN-490, a Novel Neoglycoside Antibiotic, Against Contemporary Gram-negative Clinical Isolates from Brooklyn, NY Hospitals
Claudiu Georgescu, Don-Antonio Martin, Simona Bratu, John Quale, David Landman
SUNY Downstate Medical Center
ICAAC 2009, poster # F1-842

09/13/2009 The Bactericidal Activity of the Neoglycoside ACHN-490 Against Aminoglycoside-Resistant Bacteria
Gary Zurenko, Douglas Stapert, Mary Knechtel, Nanette Nichols, Dean Shinabarger, Eliana S. Armstrong, James B. Aggen, Lee Ann Feeney, Aya Kubo, Rowena D. Matias, George H. Miller
Micromyx, Achaogen Inc.
ICAAC 2009, poster # F1-841

09/13/2009 Synthesis, Structure, and in vitro Activity of the Neoglycoside ACHN-490
James B. Aggen, Eliana S. Armstrong, Adam A. Goldblum, Paola Dozzo, Martin S. Linsell, Micah J. Gliedt, Darin J. Hildebrandt, Lee Ann Feeney,Aya Kubo, Rowena D. Matias, Sara Lopez, Marcela Gomez, Kenneth B. Wlasichuk, Raymond Diokno, George H. Miller, Heinz E. Moser
Achaogen, Inc.
ICAAC 2009, poster # F1-840

07/21/2009 Quantitative comparison of aminoglycoside nephrotoxicity in rats for effective screening and evaluation of new derivatives, and dosing rationales that minimise toxicity
C.F. Kostrub, R. Diokno, J. Aggen, G. Miller, K. Judice, P. Tulkens
Achaogen Inc., Université catholique de Louvain
ECCMID 2009 poster P 1979

07/21/2009 Surveying aminoglycoside-resistance mechanisms: a tool for the development of neoglycosides
E. Armstrong, D. Biedenbach, R. Jones, G. Miller
Achaogen Inc., JMI Laboratories
ECCMID 2009 poster P 643

07/21/2009 Ten-year trend in aminoglycoside resistance from a worldwide collection of Gram-negative pathogens (1998-2007)
D. Biedenbach, R. Jones, G. Miller, E. Armstrong
JMI Laboratories, Achaogen, Inc.
ECCMID 2009 poster P 636